Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10003155 | 0.90 | P2RX7 (0.37) | JAK2JAK1TYK2JAK3MAPT | |
| SCHEMBL10003159 | 0.90 | CDC25B (0.44) | MAPTTDP1CDC25BSMN1; SMN2TP53 | |
| SCHEMBL10003626 | 0.89 | ALDH1A1 (0.46) | MAPTALDH1A1P2RY12CDC25BSMN1; SMN2 | |
| SCHEMBL10003284 | 0.88 | ALK (0.38) | MAPTRAB9AALDH1A1FGFR1CDC25B | |
| SCHEMBL10003616 | 0.87 | CDC25B (0.43) | MAPTNPC1RAB9AALDH1A1FGFR1 | |
| SCHEMBL10003336 | 0.85 | SMN1; SMN2 (0.41) | MAPTNPC1RAB9AALDH1A1TDP1 | |
| SCHEMBL10003125 | 0.85 | RAB9A (0.42) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL10004038 | 0.84 | NPSR1 (0.41) | MAPTRAB9AALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL10002738 | 0.84 | MAPT (0.43) | MAPTNPC1RAB9AALDH1A1CDC25B | |
| SCHEMBL10003693 | 0.84 | CDC25B (0.41) | MAPTCDC25BSMN1; SMN2TP53DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471789-B9 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-03-25 | — | — | EP | disclosed |
| EP-2471789-B1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-8486965-B2 | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2471789-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | JAK2 34/4885JAK1 280/4885TYK2 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.